ArticleACS infectious diseases2026
SuperBola Cationic Biocides with an Extended Bolaamphiphilic Structure: How Much Is Too Much?
Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cationic biocides have served as effective disinfectants for nearly a century; however, our reliance on a relatively narrow set of amphiphilic structures has led to increasing levels of bacterial resistance. Recent literature has indicated that bolaamphiphiles, biscationic species bearing a nonpolar linker, show promise as advantageous architectures that display excellent antibacterial potency, while showing diminished susceptibility to bacterial resistance mechanisms. Since extended bolaamphiphilic linkers have been employed in multiple compelling structures, but had not been investigated in a systematic way, we decided to investigate structure-activity relationships of "SuperBola" structures, specifically bearing simple hydrocarbon linkers ranging from 12 to 18 carbons. In assessing 36 novel structures featuring ammonium, imidazolium, and aminopyridinum headgroups, a surprisingly wide set of potent compounds was identified, and strong bioactivity (i.e., single-digit micromolar MIC values) corresponded to an ideal amphiphilic balance, which corresponded to a consensus cLogP
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.